Tang Capital Management TECX Position
Exited4-Fund ConvergenceTang Capital Management exited their position in Tectonic Therapeutic, Inc. (TECX) in Q4 2025, after holding the stock for 7 quarters.
The position was first reported in Q2 2024 and has been tracked across 7 quarterly 13F filings.
TECX is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for TX000045- Dose A in 176 days (Oct 9, 2026), making the timing of Tang Capital's position particularly relevant.
Short interest stands at 26.1% of float with 7.0 days to cover, indicating significant bearish positioning against the stock.
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Full company profile →Short Interest
26.1%
7.0 days to cover
Tang Capital Management TECX Position History
Frequently Asked Questions
Does Tang Capital Management own TECX?
No. Tang Capital Management exited their position in Tectonic Therapeutic, Inc. (TECX) in Q4 2025. They previously held the stock for 7 quarters.
How many hedge funds own TECX?
4 specialist biotech hedge funds currently hold TECX, including EcoR1 Capital, Deep Track Capital, Baker Bros. Advisors and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy TECX?
Tang Capital Management's position in TECX was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's TECX position increasing or decreasing?
Tang Capital Management completely exited their TECX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TECXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →